Satellos Bioscience Inc.
MSCL.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -74.56% | -96.11% | -79.24% | -91.50% | -36.55% |
| Total Depreciation and Amortization | 184.31% | -43.94% | -92.18% | -96.70% | -98.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.03% | 87.80% | -50.41% | -9.20% | -11.19% |
| Change in Net Operating Assets | -378.44% | 1,226.37% | 358.92% | -109.07% | -64.25% |
| Cash from Operations | -111.79% | -91.27% | -145.76% | -263.17% | -97.47% |
| Capital Expenditure | 67.16% | 59.84% | -93.85% | -1,046.15% | -482.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 137.63% | -- | -- | -- | -- |
| Cash from Investing | 137.56% | 2,183.46% | -195,652.31% | -1,111,338.46% | -560,382.61% |
| Total Debt Issued | -- | -93.76% | -93.81% | -93.76% | -- |
| Total Debt Repaid | -- | 90.06% | -- | -- | -- |
| Issuance of Common Stock | 24.11% | -91.00% | -92.49% | 898.27% | 898.27% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -36.48% | -115.79% | -114.79% | 1,869.50% | 1,890.76% |
| Cash from Financing | 1.82% | -100.71% | -104.66% | 845.83% | 1,664.50% |
| Foreign Exchange rate Adjustments | 163.57% | -483.88% | 125.35% | -1,045.89% | -1,422.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 67.08% | -150.27% | -182.27% | 4,980.12% | 764.67% |
